Peripartum cardiomyopathy (PPCM) requires prompt, structured management. The first-line approach goes beyond standard heart failure therapy by incorporating a disease-specific intervention supported by clinical trial evidence.
Management combines standard heart failure therapy with the addition of a disease-specific agent. Where cardiac dysfunction persists, ongoing treatment is required — but the full selection criteria, sequencing, and continuation thresholds are detailed in the complete protocol.
In the presence of persistent cardiac dysfunction, medication should be continued.
Use of bromocriptine as disease-specific therapy in patients with PPCM as an addition to standard heart failure therapy has shown promising results in two clinical trials.
View source ↗